European Commission Grants Conditional Marketing Authorization for Futibatinib for the Treatment of Adults With Cholangiocarcinoma

In a post by Arndt Vogel on Twitter, it says, “European Commission Grants Conditional Marketing Authorization for Futibatinib for the Treatment of Adults With Cholangiocarcinoma.

Finally, good news for our patients in Europe as well

Efficacy demonstrated in FOENIX-CCA2.”

Source: Arndt Vogel/Twitter

Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.